D&A at other companies
Other financials
Where this comes from
Reported directly by BridgeBio Pharma in its filing.
Tagged under the XBRL concept us-gaap:DepreciationDepletionAndAmortization.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's D&A?
- BridgeBio Pharma (BBIO) reported D&A of $1.19M in Q1 2026.
- How has BridgeBio Pharma's D&A changed year-over-year?
- BridgeBio Pharma's D&A decreased by 7.6% year-over-year, from $1.28M to $1.19M.
- What is the long-term trend for BridgeBio Pharma's D&A?
- Over 4 years (2021 to 2025), BridgeBio Pharma's D&A has grown at a -1.8% compound annual growth rate (CAGR), from $5.84M to $5.43M.
- What does D&A mean?
- The non-cash expense of wearing out equipment or using up intangible assets.
- How do you interpret D&A?
- Higher values indicate a larger asset base or shorter useful life estimates for assets.
- How does D&A compare across companies?
- Standard across all capital-intensive industries; lower in pure R&D biotech firms compared to manufacturing.